ZVRA
ZEVRA THERAPEUTICS, INC.Company Information
- Company Name
- ZEVRA THERAPEUTICS, INC.
- CIK
- CIK0001434647
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ZVRA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ZVRA
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-09-12
- Last sale
- 2026-08-14
- Shares purchased (TTM)
- 28,175
- Shares sold (TTM)
- 243,680
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 44,250,011
- Shares outstanding
- 59,155,970
- Ownership
- 74.80%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- 9.83%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 145 | 96 | 62 | 54 | 48 | 37 | 34 | 54 | 39 | 43 | 43 | 43 | ||||||
| Available For Sale Securities Debt Securities Current | 76 | 105 | 129 | 145 | 155 | 25 | 36 | 35 | 10 | 10 | 25 | 40 | ||||||
| Notes And Loans Receivable Net Current | - | - | - | - | - | - | - | - | - | - | - | 42 | ||||||
| Other Short Term Investments | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Accounts And Other Receivables Net Current | 22 | 22 | 23 | 17 | 18 | 13 | 11 | 8 | 9 | 8 | 17 | 10 | ||||||
| Prepaid Expense And Other Assets Current | 5 | 5 | 7 | 7 | 4 | 4 | 4 | 2 | 3 | 2 | 2 | 2 | ||||||
| Inventory Net | 2 | 2 | 2 | 1 | 1 | 3 | 2 | - | - | - | 0 | - | ||||||
| Assets Current | 251 | 230 | 223 | 225 | 226 | 82 | 86 | 99 | 61 | 63 | 87 | 137 | ||||||
| Available For Sale Securities Debt Securities Noncurrent | 39 | 36 | 48 | 31 | 15 | 6 | 6 | 6 | - | - | 0 | - | ||||||
| Inventory Noncurrent | 0 | 0 | 1 | 1 | 1 | 11 | 11 | 9 | 10 | 12 | 10 | 0 | ||||||
| Property Plant And Equipment Net | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Goodwill | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | - | ||||||
| Other Long Term Investments | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Intangible Assets Net Excluding Goodwill | 6 | 6 | 6 | 7 | 7 | 67 | 69 | 71 | 66 | 68 | 69 | - | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | ||||||
| Assets | 303 | 279 | 285 | 270 | 256 | 173 | 178 | 192 | 144 | 151 | 172 | 139 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Lines Of Credit Current | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 38 | - | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 14 | 12 | 12 | 11 | 16 | 18 | 25 | 24 | 20 | 23 | 28 | 13 | ||||||
| Operating Lease Liability Current | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | ||||||
| Accrued Income Taxes Current | 21 | 20 | 14 | - | - | - | 0 | - | - | - | - | - | ||||||
| Other Liabilities Current | 1 | 1 | 1 | 9 | 7 | 3 | 2 | 1 | 3 | 2 | 3 | 0 | ||||||
| Liabilities Current | 49 | 47 | 39 | 26 | 29 | 27 | 34 | 34 | 30 | 30 | 74 | 22 | ||||||
| Long Term Notes Payable | - | - | - | - | - | - | - | - | - | 5 | 5 | 5 | ||||||
| Long Term Line Of Credit | - | - | - | - | - | - | - | - | - | 38 | 0 | 39 | ||||||
| Long Term Debt Noncurrent | 0 | 0 | 62 | 61 | 61 | 60 | 60 | 59 | 58 | - | 5 | - | ||||||
| Accrued Income Taxes Noncurrent | 7 | 7 | 7 | 17 | 17 | 16 | 14 | - | - | - | 0 | - | ||||||
| Operating Lease Liability Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | ||||||
| Other Liabilities Noncurrent | 2 | 2 | 2 | 4 | 3 | 5 | 5 | 6 | 7 | 9 | 7 | 0 | ||||||
| Liabilities | 85 | 73 | 130 | 137 | 139 | 132 | 138 | 122 | 112 | 102 | 110 | 72 | ||||||
| Common Stock Value | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - | - | ||||||
| Common Stock Value Outstanding | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - | - | ||||||
| Additional Paid In Capital Common Stock | 606 | 603 | 588 | 581 | 564 | 560 | 555 | 550 | 479 | 476 | 473 | 418 | ||||||
| Treasury Stock Value | -11 | -11 | -11 | -11 | -11 | -11 | -11 | -11 | -11 | -11 | -11 | -11 | ||||||
| Retained Earnings Accumulated Deficit | -375 | -384 | -422 | -434 | -434 | -508 | -505 | -470 | -436 | -416 | -400 | -339 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -2 | -2 | -1 | -2 | -2 | -0 | 1 | -0 | 0 | 0 | -0 | -0 | ||||||
| Stockholders Equity | 218 | 206 | 155 | 133 | 117 | 41 | 40 | 70 | 32 | 49 | 62 | 62 | ||||||
| Liabilities And Stockholders Equity | 303 | 279 | 285 | 270 | 256 | 173 | 178 | 192 | 144 | 151 | 172 | 139 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | - | - | - | - | - | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | ||||||
| Common Stock Shares Issued | 61 | 61 | 58 | 58 | 57 | 56 | 55 | 55 | 44 | 43 | 43 | 38 | ||||||
| Shares Outstanding | 59 | 59 | 57 | 56 | 55 | 55 | 54 | 53 | 42 | 42 | 42 | 36 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialZEVRA THERAPEUTICS, INC. (ZVRA) — SEC Financial Statements & Analysis
ZEVRA THERAPEUTICS, INC. (ZVRA) is a pharmaceutical preparations company, incorporated in DE. ZEVRA THERAPEUTICS, INC. trades on Nasdaq as: ZVRA. ZEVRA THERAPEUTICS, INC. (ZVRA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, ZEVRA THERAPEUTICS, INC. carries a market cap of $848.30M, a P/E ratio of 14.56x, a P/B ratio of 3.90x, a P/S ratio of 6.23x, an enterprise value of $702.98M, and an EV/EBITDA multiple of 8.38x. On profitability, it posts a gross margin of 79.50%, an operating margin of 60.54%, a net margin of 42.82%, a Return on Equity (ROE) of 34.80%, a Return on Assets (ROA) of 20.85%, and a Return on Invested Capital (ROIC) of 69.96%. Per share, it reports EPS of $0.98, diluted EPS of $0.95, free cash flow per share of $0.55, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 119.40% year-over-year, net income growth of 2103.59% year-over-year, and EPS growth of 1940.62% year-over-year. On the balance sheet, it maintains a current ratio of 5.17x, a quick ratio of 5.02x, working capital of $202.67M, a debt-to-equity ratio of 0.39x, a debt ratio of 0.28, an interest coverage ratio of 14.43x, free cash flow of $32.56M (TTM), and net debt of $-145.32M. Figures sourced from SEC EDGAR.
- Market Cap
- $848.30M
- P/E TTM
- 14.56x
- EPS TTM
- $0.98
- P/B TTM
- 3.90x
- ROE TTM
- 34.80%
- ROA TTM
- 20.85%
- Debt To Equity
- 0.39x
- Free Cash Flow TTM
- $32.56M
- Net Revenue TTM Growth 1Y
- 119.40%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ZEVRA THERAPEUTICS, INC. in?
ZEVRA THERAPEUTICS, INC. (ZVRA) operates in the Pharmaceutical Preparations industry.
What exchange does ZVRA trade on?
ZEVRA THERAPEUTICS, INC. (ZVRA) trades on the Nasdaq.
Where is ZEVRA THERAPEUTICS, INC. incorporated?
ZEVRA THERAPEUTICS, INC. is incorporated in DE.
When was ZEVRA THERAPEUTICS, INC. (ZVRA)'s most recent SEC filing?
ZEVRA THERAPEUTICS, INC. (ZVRA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is ZVRA's market cap?
ZEVRA THERAPEUTICS, INC. (ZVRA) has a market capitalization of $848.30M as of 2026-06-30.
What is ZVRA's P/E ratio?
ZEVRA THERAPEUTICS, INC. (ZVRA)'s trailing twelve month P/E ratio is 14.56x as of 2026-06-30.
What is ZVRA's EPS (earnings per share)?
ZEVRA THERAPEUTICS, INC. (ZVRA)'s trailing twelve month EPS is $0.98 as of 2026-06-30.
What is ZVRA's ROE (return on equity)?
ZEVRA THERAPEUTICS, INC. (ZVRA)'s trailing twelve month Return on Equity (ROE) is 34.80% as of 2026-06-30.
What is ZVRA's ROA (return on assets)?
ZEVRA THERAPEUTICS, INC. (ZVRA)'s trailing twelve month Return on Assets (ROA) is 20.85% as of 2026-06-30.
What is ZVRA's ROIC (return on invested capital)?
ZEVRA THERAPEUTICS, INC. (ZVRA)'s trailing twelve month Return on Invested Capital (ROIC) is 69.96% as of 2026-06-30.
What is ZVRA's EV/EBITDA?
ZEVRA THERAPEUTICS, INC. (ZVRA)'s trailing twelve month EV/EBITDA is 8.38x as of 2026-06-30.